RxDoctor Payments Data

Guillermo Moguel Cobos

Neurology · Phoenix, AZNPI 1629267596

Payments from drug & device makers

$74,463in general payments, 2019–2025

Across 61 payments — averaging $1220.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$57K
  • MDD US Operations, LLC$17K
  • Teva Pharmaceuticals USA, Inc.$92
  • Abbott$40
  • AbbVie$17
  • Travere Therapeutics, Inc.$1

What the payments were for

  • Food & beverage$5738%
  • Education$9362%

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$74,463 in reported general payments places this provider in the 80th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$693,934
Medicare patients
373
Services billed
75,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate121$1,001,526
NuplazidPimavanserin Tartrate117$653,434
AustedoDeutetrabenazine38$439,779
RytaryCarbidopa/Levodopa171$349,429
GocovriAmantadine Hcl75$289,617
BotoxOnabotulinumtoxina72$223,672
NeuproRotigotine86$95,861
AmantadineAmantadine Hcl492$41,263
NourianzIstradefylline16$33,611
Carbidopa-LevodopaCarbidopa/Levodopa669$22,797
MyrbetriqMirabegron33$15,101
CrexontCarbidopa/Levodopa17$15,067
Emgality PenGalcanezumab-Gnlm20$14,674
Rasagiline Mesylate61$13,490
Nurtec OdtRimegepant Sulfate12$12,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$92$439,77938 claims
MDD US Operations, LLCGocovri$16,817$289,61775 claims
AbbVieBotox, Ubrelvy$17$235,03583 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 388 neurology providers in Arizona.

Other neurology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →